JP5275247B2 - ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の検出および糖尿病の合併症の有無の検出 - Google Patents

ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の検出および糖尿病の合併症の有無の検出 Download PDF

Info

Publication number
JP5275247B2
JP5275247B2 JP2009535557A JP2009535557A JP5275247B2 JP 5275247 B2 JP5275247 B2 JP 5275247B2 JP 2009535557 A JP2009535557 A JP 2009535557A JP 2009535557 A JP2009535557 A JP 2009535557A JP 5275247 B2 JP5275247 B2 JP 5275247B2
Authority
JP
Japan
Prior art keywords
diabetes
pro
marker
detection
proadm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009535557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509575A (ja
JP2010509575A5 (enExample
Inventor
アンドレアス ベルクマン，
ニールス モルゲンターラー，
ヤナ パパッソチロー，
ヨアキム ストラック，
Original Assignee
ベー．エル．アー．ハー．エム．エス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベー．エル．アー．ハー．エム．エス ゲーエムベーハー filed Critical ベー．エル．アー．ハー．エム．エス ゲーエムベーハー
Publication of JP2010509575A publication Critical patent/JP2010509575A/ja
Publication of JP2010509575A5 publication Critical patent/JP2010509575A5/ja
Application granted granted Critical
Publication of JP5275247B2 publication Critical patent/JP5275247B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009535557A 2006-11-08 2007-11-08 ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の検出および糖尿病の合併症の有無の検出 Active JP5275247B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006052916A DE102006052916A1 (de) 2006-11-08 2006-11-08 Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM
DE102006052916.2 2006-11-08
PCT/DE2007/002018 WO2008055491A2 (de) 2006-11-08 2007-11-08 Diagnose und risikostratifizierung von diabetes mellitus mittels mr-proadm

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012235494A Division JP2013047689A (ja) 2006-11-08 2012-10-25 ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の診断およびリスク層化

Publications (3)

Publication Number Publication Date
JP2010509575A JP2010509575A (ja) 2010-03-25
JP2010509575A5 JP2010509575A5 (enExample) 2010-11-25
JP5275247B2 true JP5275247B2 (ja) 2013-08-28

Family

ID=39277540

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009535557A Active JP5275247B2 (ja) 2006-11-08 2007-11-08 ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の検出および糖尿病の合併症の有無の検出
JP2012235494A Pending JP2013047689A (ja) 2006-11-08 2012-10-25 ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の診断およびリスク層化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012235494A Pending JP2013047689A (ja) 2006-11-08 2012-10-25 ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の診断およびリスク層化

Country Status (7)

Country Link
US (2) US20100035275A1 (enExample)
EP (1) EP2097748B1 (enExample)
JP (2) JP5275247B2 (enExample)
CN (2) CN101568833B (enExample)
DE (1) DE102006052916A1 (enExample)
ES (1) ES2393262T3 (enExample)
WO (1) WO2008055491A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2016394A4 (en) 2006-04-04 2013-04-24 Singulex Inc METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES
DE102007009751A1 (de) 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
ES2795003T3 (es) * 2008-10-07 2020-11-20 Brahms Gmbh Biomarcador para la predicción de los primeros eventos adversos
EP2180322A1 (en) * 2008-10-22 2010-04-28 BRAHMS Aktiengesellschaft Prognostic biomarkers for the progression of primary chronic kidney disease
US20110262939A1 (en) * 2008-10-31 2011-10-27 B.R.A.H.M.S Gmbh Methods and assays for classifying foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system
CN102203608B (zh) * 2008-10-31 2016-11-23 B.R.A.H.M.S有限公司 用于与代谢综合征、心血管疾病和/或胰岛素抗性相关的病症的诊断、预后、监测和治疗追踪的体外方法
JP5584695B2 (ja) * 2008-11-11 2014-09-03 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｄｍ及びｂｎｐのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
CN102472752B (zh) * 2009-08-28 2015-08-19 B.R.A.H.M.S有限公司 用于不良事件的预后的降钙素原
RU2017110678A (ru) * 2010-11-01 2019-01-24 Б.Р.А.Х.М.С Гмбх Оценка прогноза и риска пациентов с неспецифическими жалобами
AU2012219582A1 (en) * 2011-02-21 2013-08-22 Fibrostatin S.L. Methods for treating and diagnosing disease
EP2533052A1 (en) * 2011-06-07 2012-12-12 B.R.A.H.M.S GmbH Diagnostic use of proSomatostatin
CN104714020B (zh) * 2013-12-12 2016-05-25 张曼 尿液内源性α胰蛋白酶抑制剂重链H4在2型糖尿病合并冠心病中的应用
CN119199150A (zh) * 2015-11-27 2024-12-27 B.R.A.H.M.S 有限公司 作为对象的细胞外容量状态的标志物的MR-proADM
RU2765212C2 (ru) * 2016-08-09 2022-01-26 Б.Р.А.Х.М.С. Гмбх Гистоны и/или proadm в качестве маркеров, свидетельствующих о неблагоприятном событии
JP7194673B2 (ja) * 2016-08-09 2022-12-22 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 臓器障害を示すマーカーとしてのヒストンおよび／またはｐｒｏＡＤＭ
EP3438668A1 (en) * 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnosis and risk stratification of fungal infections
EP3682247B1 (en) * 2017-09-13 2022-02-09 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
US11892456B2 (en) * 2017-11-17 2024-02-06 Tokai University Educational System Method of examining diabetic complication

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69602756T2 (de) * 1995-08-18 2000-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6756783B2 (en) * 1999-06-01 2004-06-29 Merlin Technology, Inc Multi-frequency boring tool locating system and method
ES2254220T3 (es) * 1999-09-10 2006-06-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Determinacion de proteinas de enlace con la adrnomedulina.
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
WO2004097423A1 (en) * 2003-04-25 2004-11-11 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
ES2300681T3 (es) * 2004-07-22 2008-06-16 Brahms Aktiengesellschaft Procedimiento para el diagnostico y tratamiento de pacientes criticos con endotelina, agonistas de endotelina y antagonistas de adrenomedulina.
GB2418995B (en) * 2004-09-29 2006-08-16 Bookham Technology Plc Apodised binary grating
FI20050011L (fi) * 2005-01-05 2006-07-06 Jurilab Ltd Oy Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi

Also Published As

Publication number Publication date
DE102006052916A1 (de) 2008-05-15
CN101568833A (zh) 2009-10-28
CN104198735B (zh) 2018-01-30
JP2010509575A (ja) 2010-03-25
US20100035275A1 (en) 2010-02-11
WO2008055491A2 (de) 2008-05-15
CN104198735A (zh) 2014-12-10
HK1203090A1 (en) 2015-10-16
WO2008055491A3 (de) 2008-08-21
HK1137805A1 (en) 2010-08-06
US20160169912A1 (en) 2016-06-16
JP2013047689A (ja) 2013-03-07
CN101568833B (zh) 2014-09-10
ES2393262T3 (es) 2012-12-19
EP2097748A2 (de) 2009-09-09
EP2097748B1 (de) 2012-08-08

Similar Documents

Publication Publication Date Title
JP5275247B2 (ja) ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の検出および糖尿病の合併症の有無の検出
Cracowski et al. The potential of biomarkers in pulmonary arterial hypertension
US8524462B2 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
Palazzuoli et al. Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin
JP2010509575A5 (enExample)
CN105934674B (zh) 用于在由利钠肽指导的心力衰竭患者中风险评估和治疗监测的生物标记物
Iqbal et al. Novel biomarkers for heart failure
WO2006131529A1 (en) Use of nt-proanp and nt-probnp for diagnosing cardiac diseases
EP2376919B1 (en) Combined natriuretic peptide assays
EP3497450B1 (en) Histones and/or proadm as markers indicating organ dysfunction
WO2010125165A1 (en) Means and methods for diagnosing a heart failure associated kidney damage in individuals in need of a suitable therapy
WO2011073382A1 (en) Gdf-15 and/or troponin t for predicting kidney failure in heart surgery patients
US20110263438A1 (en) Diagnosis and complication risk assessment of pancreatic diabetes using procalcitonin
CN102203608B (zh) 用于与代谢综合征、心血管疾病和/或胰岛素抗性相关的病症的诊断、预后、监测和治疗追踪的体外方法
Singhal et al. Bedside biomarkers in pediatric cardio renal injuries in emergency
Taskapan et al. NGAL and NT-proBNP levels in diabetic patients with macroproteinuria
DK2626704T3 (en) Diagnosis of pancreatic diabetes in patients with normal blood leucocyte counts using procalcitonin
US20110081725A1 (en) Assessment of complications of patients with type 1 diabetes
Hu et al. Urinary C-type natriuretic peptide excretion: a promising biomarker to detect underlying renal injury and remodeling both acutely and chronically
Mirna et al. Diverging Concentrations of Soluble Suppression of Tumorigenicity (sST2) Analyzed by two Different Assays-a Limitation for its use in Clinical Practice?
US20110207629A1 (en) Predicting cardiovascular events and renal failure in type 1 diabetics
HK1203090B (en) Diagnosis and risk assessment of pancreatic diabetes using mr-proadm
WO2023208993A1 (en) Biomarkers of diabetic nephropathy
HK1137805B (en) Diagnosis and risk assessment of pancreatic diabetes using mr-proadm
Simic-Ogrizovic et al. Risk factors associated with coronary artery calcification should be examined before kidney transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101005

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120116

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120417

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120515

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121025

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130515

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5275247

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250